This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The gene-editing technology allows for precise, directed changes to genomic DNA. Under the terms of the deal, the company will receive non-exclusive rights to CRISPR/Cas9, a gene-editing technology of CRISPR Therapeutics, for the development of potentially curative T1D cell therapies. The system comprises the Cas9 enzyme and a guide RNA.
7, 2020 — After starting a drug that’s officially approved to treat a type of blood cancer, a young man with type 1 diabetes was able to stop using insulin. He’s been off insulin since August 2018 — more than two years. WEDNESDAY, Oct. No treatments are approved for reversing type 1 diabetes.
As the world’s first PPAR pan agonist that completed two confirmatory phase III clinical trials, Chiglitazar Sodium has shown significant and long-lasting hypoglycemic effects in a series of clinical studies, as well as other comprehensive effects including significant insulin sensitization and blood lipid regulation.
In May 2020, Freenome initiated AI-EMERGE, a clinical study for the AI-Genomics blood test has been completed, which collected samples from up to 3,000 patients in the US and Canada. The device is worn on the patients’ body, which contains a biharmonic cartridge in it that carries insulin and glucagon.
Illumina says TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims. Users can also manually log details such as blood glucose readings, meals, exercise or insulin doses. The device is half the size of Medtronics previous CGMs.
The two companies have signed a five-year collaboration to leverage genomics and artificial intelligence (AI) to discover and develop new treatments for diseases with unmet medical needs. Deerfield and Illumina win the Research and Development award this year due to their commitment to research into AI-driven therapies. Civica JAAQ Sanofi.
Hormones (includes recombinant insulin, erythropoietin and growth hormones) Enzyme replacement therapies used in treatment of rare genetic disorders such as Gaucher disease. Automation and High-Throughput Screening: The development of automated high throughput techniques for large scale protein production, enabling low cost and reduced time.
Rhesus Macaque Genome Reference Includes 85 Million Genetic Variants. Researchers at Baylor College of Medicine , the University of Missouri and the University of Washington created a new reference genome assembly, identifying more than 85 million genetic variants in the rhesus macaque.
1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
million (DKK 585 million) to the Ancient Environmental Genomics Initiative for Sustainability (AEGIS), advancing climate-resilient crops and showcasing its broader commitment to global sustainability. Novo Nordisks Circular for Zero initiative aims to eliminate waste across product lifecycles, including eco-friendly insulin delivery systems.
The first was insulin – Frederick Banting and colleagues managed to isolate insulin that could treat diabetes, up until that point a fatal condition. The period between 1918 and 1939 was marked by two breakthroughs that presaged the arrival of the pharma industry as we know it today. New challenges in an age of innovation.
At Illumina, the ‘era of the genome’ has arrived.
Viatris Expects First “Interchangeable” Designation in July 2021 For Insulin Products ( Big Molecule Watch ).
Viatris Expects First “Interchangeable” Designation in July 2021 For Insulin Products ( Big Molecule Watch ).
Coronavirus Pandemic.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content